We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Outsourcer Broke Rules for CGMP, Sterile Production, FDA Says

Outsourcer Broke Rules for CGMP, Sterile Production, FDA Says

November 10, 2017

The FDA cited an outsourcing drug compounder in Arkansas for failure to meet sterile production standards, according to a warning letter from the agency.

The company, U.S. Compounding, of Conway, violated CGMP rules via failures in monitoring environmental conditions for aseptic processing, in designing its work spaces to prevent contamination, in laboratory testing of finished products and in investigation of out-of-specification products, the letter said.

FDA inspections in 2015 and 2016 also found violations of sterile production regulations that apply to all compounders and drugmakers, including an influx of poor quality air into the sterile workspace and unsealed, rough-cut holes and duct work in the workspace ceiling that could allow for contamination, the letter said.

U.S. Compounding is one of 73 outsourcing facilities registered under the Drug Quality and Security Act, a law passed in 2013 in response to the meningitis deaths of 76 individuals who were injected with contaminated drugs produced by New England Compounding Center (NECC) in Massachusetts. The 2013 law permits compounders to produce drugs that are not tied to individual patient prescriptions provided they register with the FDA as outsourcers. The registration subjects them to current good manufacturing practice regulations that do not apply to other compounders, who may produce drugs only for individual patient prescriptions.

NECC pharmacist Glenn Chin was convicted Oct. 25 of mail fraud and racketeering, but acquitted on murder charges; co-founder Barry Cadden received similar verdicts earlier in the year.

U.S. Compounding has resumed operations “after cessation of sterile operations and recall of sterile products,” the FDA said.

View today's stories

Pharmaceuticals Inspections and Audits

Upcoming Events

  • 10Mar

    FDA Drug GMP Facility Inspections During the Pandemic

  • 16Mar

    Pharmaceutical Naming Regulation: Understanding the Latest Developments

  • 18Mar

    Pharmaceutical Postmarket Surveillance: Latest Developments in the Era of COVID-19

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 30Mar

    Data Integrity for GMP/Postmarket Professionals: Core Requirements, Expectations and Challenges

  • 06Apr

    Medical Device Cybersecurity: Understand the Latest Developments

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • Vaccine needle

    Turkish Researchers Downgrade Sinovac’s COVID-19 Vaccine Efficacy Rate

  • Luminex logo

    Luminex Receives EUA for Expanded Respiratory Pathogen Panel, Clearing It for COVID-19

  • Acquires -Acquired

    Amgen to Buy Five Prime Therapeutics for $1.9 Billion

  • abbott-logo.gif

    Abbott Secures EUA for COVID-19 Combination Test

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing